CD86 and neoplasm: Tumor cell FC analysis found no differences in the proportions of total myeloid cells, TAMs, monocytes, granulocytes, MRhi TAMs, or MHCII+CD86+ TAMs on day 21 in control or C/EBPβ-deleted prostate cancer recipients (Fig 3B).